Arginine

Arginine

SCHEMBL4807560

N=C(N)NCCC[C@H](N)C(=O)O.NCC(=O)O.O=C(O)[C@@H]1CCCN1.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PRCP P42785 2/20 0.38
OTC P00480 1/20 0.36
NOS2 P35228 3/20 0.35
NOS3 P29474 2/20 0.35
NOS1 P29475 2/20 0.35
DDAH1 O94760 1/20 0.35
GSR P00390 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
DPP7 Q9UHL4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL8582228 1.00 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL8697426 1.00 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL1675364 1.00 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL28774540 1.00 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL3087368 1.00 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL1417757 1.00 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL29164461 1.00 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL2123729 0.97 PRCP (0.36) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL28470370 0.97 PRCP (0.38) PRCPOTCNOS2NOS3NOS1
Arginine SCHEMBL6535144 0.96 PRCP (0.37) PRCPOTCNOS2NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3149485-B1 METHOD FOR DIAGNOSING A DISEASE OR A RISK TO DEVELOP A DISEASE TRANSMITTED VIA THE ALTERNATIVE PATHWAY OF THE COMPLEMENT SYSTEM UNIV TUEBINGEN MEDIZINISCHE FAKULTAET (DE) 2021-03-03 EP claimed
CN-110691972-A Disposable system for hemostatic function analysis 海默索尼克斯有限公司 2020-01-14 CN claimed
US-20170160291-A1 METHOD FOR THE DIAGNOSIS OF OR RISK FOR A DISEASE MEDIATED VIA THE ALTERNATIVE PATHWAY OF THE COMPLEMENT SYSTEM EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) 2017-06-08 US claimed
WO-2004110470-A2 USE OF COLLAGEN PEPTIDES TO INHIBIT INFECTION THE UNIVERSITY OF BRISTOL (GB) 2004-12-23 WO claimed
US-20230228734-A1 METHOD FOR FIBRINOGEN MEASUREMENT A&T CORPORATION (JP) 2023-07-20 US disclosed
CN-115561306-A Disposable system for hemostatic function analysis 海默索尼克斯有限公司 2023-01-03 CN disclosed
CN-110691972-B Disposable system for hemostatic function analysis 海默索尼克斯有限公司 2022-11-04 CN disclosed
US-20220120768-A1 REAGENT FOR MEASURING FIBRINOGEN A&T CORPORATION (JP) 2022-04-21 US disclosed
WO-2020116556-A1 REAGENT FOR MEASURING FIBRINOGEN 株式会社エイアンドティー 2020-06-11 WO disclosed
CN-110691972-A Disposable system for hemostatic function analysis 海默索尼克斯有限公司 2020-01-14 CN disclosed
US-10416173-B2 Method for the diagnosis of or risk for a disease mediated via the alternative pathway of the complement system EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) 2019-09-17 US disclosed
US-20170160291-A1 METHOD FOR THE DIAGNOSIS OF OR RISK FOR A DISEASE MEDIATED VIA THE ALTERNATIVE PATHWAY OF THE COMPLEMENT SYSTEM EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) 2017-06-08 US disclosed
US-20040077028-A1 Assay for thrombocytopenia associated with administration of platelet GPIIb-IIIa receptor antagonists MASSACHUSETTS, UNIVERSITY OF 2004-04-22 US disclosed
WO-2004017900-A2 ASSAY FOR THROMBOCYTOPENIA ASSOCIATED WITH ADMINISTRATION OF PLATELET GPIIB-IIIA RECEPTOR ANTAGONISTS UNIVERSITY OF MASSACHUSETTS (US) 2004-03-04 WO disclosed
US-20030109431-A1 Pro-inflammatory fibrinopeptide VETERANS AFFAIRS, U.S. DEPARTMENT OF 2003-06-12 US disclosed
US-20030109431-A1 Pro-inflammatory fibrinopeptide VETERANS AFFAIRS, U.S. DEPARTMENT OF 2003-06-12 US disclosed
US-20020160523-A1 Method for monitoring resting and activated platelets in unfixed blood samples PPD BIOMARKER SERVICES, LLC 2002-10-31 US disclosed
WO-2002025280-A1 METHOD FOR MONITORING RESTING AND ACTIVATED PLATELETS IN UNFIXED BLOOD SAMPLES SURROMED, INC. (US) 2002-03-28 WO disclosed
US-5508202-A MIXING SAMPLE AND FIBRIN PRECIPITATION INHIBITOR, ADDING THROMBIN SOLUTION, DETERMINING FIBRIN COAGULATION TIME IN PRESENCE OF CALCIUM ION, CAMPARING COAGULATION TIME WITH NORMAL COAGULATION TIME NIPPON SHOJI KAISHA, LTD. (JP) 1996-04-16 US disclosed
EP-0632270-A1 METHOD OF ASSAYING ACTIVITY OF BLOOD COAGULATION FACTOR XIII AND REAGENT KIT THEREFOR NIPPON SHOJI KABUSHIKI KAISHA (JP) 1995-01-04 EP disclosed